BioWorld

May 2, 2007

Series A And B Rounds Up As Early Stage Model Evolves

Of the $2.1 billion in venture capital invested in global biotechnology companies last quarter, the majority went into earlier-stage financings, according to data from BioWorld Financial Watch and BioWorld Snapshots. (BioWorld Today) Read More

House Hearing Probes Range Of Ways To Improve The FDA

Optimer's CDAD Drug Starts Second Pivotal Phase III Trial

NewCo News: Start-Up Solace Raises $15M In Series A For Pain Drugs

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...